序贯疗法根除初治失败幽门螺杆菌疗效观察_West China Medical Journal

Authors：

黄忠 , 李智 , 侯聪

Corresponding author：

Keywords：

序贯疗法; 四联疗法; 幽门螺杆菌

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　分析总结雷贝拉唑、阿莫西林、克拉霉素、替硝唑组成的10日序贯疗法根除初治失败幽门螺杆菌（Helicobacter pylori，Hp）的疗效。　方法　将2009年5月-2011年5月在消化科门诊及住院经胃镜确诊的胃、十二指肠溃疡患者65例，经标准三联疗法治疗4周后Hp仍阳性的患者随机分为两组，治疗组33例前5 d用雷贝拉唑10 mg、阿莫西林1.0，每日2次口服，后5 d用雷贝拉唑10 mg、克拉霉素500 mg、替硝唑500 mg，每日2次口服；对照组32例用雷贝拉唑10 mg、枸橼酸铋钾600 mg、呋喃唑酮0.1 g、阿莫西林1.0 g，每日2次，疗程10 d。停药4周后复查Hp。　结果　治疗组Hp根除率81.8%，对照组75.0%，两组比较无统计学意义（P gt;0.05）。不良反应率分别为12.1%和34.3%，两组比较有统计学意义（P lt;0.05）。　结论　序贯疗法对初治失败Hp根除率高于四联疗法但无统计学意义，不良反应率低于对照组，可作为根除初治失败Hp的一种有效方案。

Citation： 黄忠,李智,侯聪. 序贯疗法根除初治失败幽门螺杆菌疗效观察. West China Medical Journal, 2011, 26(10): 1539-1540. doi: Copy

1.	Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections [J].Nat Clin Pract Gastroenterol Hepatol, 2008, 5(6): 321-331.
2.	Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer:a prospective controlled study[J].Aliment pharmacol Ther, 2005, 21(12): 1419-1424.
3.	Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children:a randomized trial[J]. Gastroenterology, 2005, 129(5): 1414-1419.
4.	Bago P, Vcer A, Tomic M, et al. High eradication rate of H.pylori with moxifloxacin-based treatment:a randomized controlled trial[J].Wien Klin Wochenschr, 2007, 119(11-12): 372-378.
5.	De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori[J]. Ann Inter Med, 2006, 144(2): 94-100.
6.	De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance:an unresolved question[J]. FEMS Microbiol Rev, 2006, 30(1):36-52.
7.	Zechini B, Versace I. Inhibitiors of multidrug resistant efflux systems in bacteria[J]. Recent Pat Antiinfect Drug Discov, 2009, 4(1): 37-50.
8.	Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use[J]. Biochen Pharmacol, 2006, 71(7): 910-918.
9.	Hong EJ, Park DI, Oh SJ, et al. Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors[J].Korean J Gastroenterol, 2008, 52(2): 80-85.
10.	Aeschlimann JR, Dresser LD, Kaatz GW, et al. Effects of NorA in-hibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin,and norfloxacin in genetically related strains of staphylococcus aurens[J]. Antimicrob Agents Chemother, 1999, 43(2): 335-340.

1. 　Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections [J].Nat Clin Pract Gastroenterol Hepatol, 2008, 5(6): 321-331.
2. 　Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer:a prospective controlled study[J].Aliment pharmacol Ther, 2005, 21(12): 1419-1424.
3. 　Francavilla R, Lionetti E, Castellaneta SP, et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children:a randomized trial[J]. Gastroenterology, 2005, 129(5): 1414-1419.
4. 　Bago P, Vcer A, Tomic M, et al. High eradication rate of H.pylori with moxifloxacin-based treatment:a randomized controlled trial[J].Wien Klin Wochenschr, 2007, 119(11-12): 372-378.
5. 　De Francesco V, Margiotta M, Zullo A, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori[J]. Ann Inter Med, 2006, 144(2): 94-100.
6. 　De Rossi E, Aínsa JA, Riccardi G. Role of mycobacterial efflux transporters in drug resistance:an unresolved question[J]. FEMS Microbiol Rev, 2006, 30(1):36-52.
7. 　Zechini B, Versace I. Inhibitiors of multidrug resistant efflux systems in bacteria[J]. Recent Pat Antiinfect Drug Discov, 2009, 4(1): 37-50.
8. 　Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-A vision for applied use[J]. Biochen Pharmacol, 2006, 71(7): 910-918.
9. 　Hong EJ, Park DI, Oh SJ, et al. Comparison of Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia and peptic ulcer diseases according to proton pump inhibitors[J].Korean J Gastroenterol, 2008, 52(2): 80-85.
10. 　Aeschlimann JR, Dresser LD, Kaatz GW, et al. Effects of NorA in-hibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin,and norfloxacin in genetically related strains of staphylococcus aurens[J]. Antimicrob Agents Chemother, 1999, 43(2): 335-340.

West China Medical Journal

序贯疗法根除初治失败幽门螺杆菌疗效观察

Abstract Full text Figures/Tables Video References Cited by

Format

Content